FindTrial
Sign In

J1G-MC-LAKI: A Study of Remternetug Versus Placebo in Early Alzheimer’s Disease Participants at Risk for Cognitive and Functional Decline

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-515656-20-00
Acronym
J1G-MC-LAKI
Enrollment
43
Registered
2025-03-11
Start date
2025-04-15
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer’s Disease

Brief summary

Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rate (CDR). CDR is a clinician-rated scale that provides an overall assessment of the participant's stage and degree of impairment across the continuum of early Alzheimer's Disease (AD).

Interventions

DRUGRemternetug
DRUGPlacebo to match LY

Sponsors

Eli Lilly & Co.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rate (CDR). CDR is a clinician-rated scale that provides an overall assessment of the participant's stage and degree of impairment across the continuum of early Alzheimer's Disease (AD).—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026